HomeCompareFGEN vs QSR

FGEN vs QSR: Dividend Comparison 2026

FGEN yields 22.05% · QSR yields 3.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FGEN wins by $58.1K in total portfolio value
10 years
FGEN
FGEN
● Live price
22.05%
Share price
$9.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$82.7K
Annual income
$8,340.12
Full FGEN calculator →
QSR
QSR
● Live price
3.40%
Share price
$73.76
Annual div
$2.51
5Y div CAGR
-0.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$387.88
Full QSR calculator →

Portfolio growth — FGEN vs QSR

📍 FGEN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFGENQSR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FGEN + QSR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FGEN pays
QSR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FGEN
Annual income on $10K today (after 15% tax)
$1,874.31/yr
After 10yr DRIP, annual income (after tax)
$7,089.10/yr
QSR
Annual income on $10K today (after 15% tax)
$289.25/yr
After 10yr DRIP, annual income (after tax)
$329.70/yr
At 15% tax rate, FGEN beats the other by $6,759.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FGEN + QSR for your $10,000?

FGEN: 50%QSR: 50%
100% QSR50/50100% FGEN
Portfolio after 10yr
$53.7K
Annual income
$4,364.00/yr
Blended yield
8.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on QSR right now

FGEN
Analyst Ratings
5
Buy
7
Hold
2
Sell
Consensus: Hold
Price Target
$28.00
+208.7% upside vs current
Range: $28.00 — $28.00
Altman Z
-20.3
Piotroski
6/9
QSR
Analyst Ratings
27
Buy
15
Hold
2
Sell
Consensus: Buy
Price Target
$81.57
+10.6% upside vs current
Range: $71.00 — $90.00
Altman Z
1.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FGEN buys
0
QSR buys
0
No recent congressional trades found for FGEN or QSR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFGENQSR
Forward yield22.05%3.40%
Annual dividend / share$2.00$2.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-0.8%
Portfolio after 10y$82.7K$24.7K
Annual income after 10y$8,340.12$387.88
Total dividends collected$49.4K$3.7K
Payment frequencyquarterlyquarterly
SectorStockStock
Analyst consensusHoldBuy
Analyst price target$28.00$81.57

Year-by-year: FGEN vs QSR ($10,000, DRIP)

YearFGEN PortfolioFGEN Income/yrQSR PortfolioQSR Income/yrGap
1← crossover$12,905$2,205.07$11,038$337.57+$1.9KFGEN
2$16,468$2,659.50$12,156$345.43+$4.3KFGEN
3$20,792$3,171.71$13,359$352.69+$7.4KFGEN
4$25,990$3,742.62$14,654$359.36+$11.3KFGEN
5$32,182$4,372.22$16,045$365.45+$16.1KFGEN
6$39,494$5,059.61$17,539$370.97+$22.0KFGEN
7$48,062$5,803.04$19,143$375.96+$28.9KFGEN
8$58,026$6,599.92$20,863$380.42+$37.2KFGEN
9$69,535$7,446.93$22,708$384.39+$46.8KFGEN
10$82,743$8,340.12$24,685$387.88+$58.1KFGEN

FGEN vs QSR: Complete Analysis 2026

FGENStock

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Full FGEN Calculator →

QSRStock

Restaurant Brands International Inc. operates as quick service restaurant company in Canada and internationally. It operates through four segments: Tim Hortons (TH), Burger King (BK), Popeyes Louisiana Kitchen (PLK), and Firehouse Subs (FHS). The company owns and franchises TH chain of donut/coffee/tea restaurants that offer blend coffee, tea, and espresso-based hot and cold specialty drinks; and fresh baked goods, including donuts, Timbits, bagels, muffins, cookies and pastries, grilled paninis, classic sandwiches, wraps, soups, and others. It is also involved in owning and franchising BK, a fast food hamburger restaurant chain, which offers flame-grilled hamburgers, chicken and other specialty sandwiches, french fries, soft drinks, and other food items; and PLK quick service restaurants that provide Louisiana style fried chicken, chicken tenders, fried shrimp and other seafood, red beans and rice, and other regional items. In addition, the company owns and franchises FHS restaurants quick service restaurants that offer subs, soft drinks, and local specialties. As of February 15, 2022, the company had approximately 29,000 restaurants in 100 countries under the Tim Hortons, Burger King, Popeyes, And Firehouse Subs brands. Restaurant Brands International Inc. was founded in 1954 and is headquartered in Toronto, Canada.

Full QSR Calculator →
📬

Get this FGEN vs QSR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FGEN vs SCHDFGEN vs JEPIFGEN vs OFGEN vs KOFGEN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.